2024-09-18 - Analysis Report
## AMGN Stock Analysis Report

**Company Overview:** Amgen Inc. (AMGN) is a leading biotechnology company focused on developing and delivering innovative medicines for serious illnesses.

**Performance Analysis:**

**1. Performance Comparison:**

* AMGN's cumulative return is 59.02%, while the S&P 500 (VOO) has a cumulative return of 89.02%.
* AMGN lags behind the S&P 500 by -30.00%.
* The relative divergence of -30.00 puts it at the 47.37 percentile of its historical range (maximum: 9.31, minimum: -65.02), suggesting that AMGN's underperformance is within a typical range.

**2. Recent Price Movement:**

* Closing Price: 335.26
* 5-day Moving Average: 331.34
* 20-day Moving Average: 328.79
* 60-day Moving Average: 325.62

The price movement is showing a slightly bullish trend, as the closing price is above all three moving averages.

**3. Technical Indicators:**

* RSI: 62.02 - The RSI is above 50, suggesting a bullish trend.
* PPO: 0.16 -  The positive PPO value indicates a potential upward momentum.
* Delta_Previous_Relative_Divergence: 4.61 (+) -  Positive value indicates a short-term upward trend.
* Expected_Return: 7.42% -  The potential 5-year expected return is positive.

**4. Recent Earnings & Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-07 | 1.39 | 8.39 B$ |
| 2024-05-03 | -0.21 | 7.45 B$ |
| 2023-10-31 | 3.23 | 6.90 B$ |
| 2023-08-04 | 2.58 | 6.99 B$ |
| 2024-08-07 | 2.58 | 6.99 B$ |

* AMGN's most recent earnings report (2024-08-07) shows EPS of 1.39 and revenue of 8.39 billion dollars. 
* The EPS beat analysts' expectations, indicating positive performance. 

**Overall Analysis:**

AMGN's stock price is showing a slight bullish trend, supported by positive technical indicators, recent earnings exceeding expectations, and a positive projected return. Although the company's return lags behind the S&P 500, its current performance is within historical ranges.  The positive outlook suggests potential growth opportunities for investors. 

**Disclaimer:** This analysis is for informational purposes only and should not be considered investment advice. 
